Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0476089 (
endometrial cancer
)
11,379
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Background:
Endometrial cancer
(EC) is an intractable gynecological cancer with increasing incidence and mortality worldwide. Accumulating studies indicated that long noncoding RNA nuclear enriched autosomal transcript 1 (
NEAT1
) was a novel oncogene implicated in a variety of cancers. However, whether
NEAT1
could accelerate cell growth in EC is unclear.
Methods:
NEAT1
, microRNA (miR)-202-3p, and T cell immunoglobulin and mucin domain 4 (
TIMD4
) levels were detected by quantitative real-time polymerase chain reaction. Cell proliferation and apoptosis were examined by cell counting kit-8 and flow cytometry. Transwell assay was employed for the evaluation of cell migration and invasion. The relationship between miR-202-3p and
NEAT1
or
TIMD4
was determined by luciferase reporter system.
TIMD4
protein expression was assessed by Western blot assay.
Results:
NEAT1
was upregulated, whereas miR-202-3p was downregulated in EC tumors and cells. Depletion of
NEAT1
restrained EC cell proliferation, migration, invasion, and improved apoptosis. MiR-202-3p was targeted by
NEAT1
and could bind to
TIMD4
. Subsequently, it is observed that miR-202-3p inhibitor neutralized NEAT1 silencing mediated suppression on EC cell progression. Meanwhile,
TIMD4
rescued miR-202-3p induced inhibition on cell progression in EC. Furthermore, it was obvious that
NEAT1
facilitated
TIMD4
expression by absorbing miR-202-3p in EC.
Conclusions:
Upregulation of NEAT1 accelerated EC cell progression through sponging miR-202-3p to facilitate
TIMD4
expression, providing potential novel treatment method for EC.
...
PMID:Overexpression of Nuclear Enriched Autosomal Transcript 1 Facilitates Cell Proliferation, Migration Invasion, and Suppresses Apoptosis in Endometrial Cancer by Targeting MicroRNA-202-3p/T Cell Immunoglobulin and Mucin Domain 4 Axis. 3288 42